Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women.
about
Is protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysisGetting to 90-90-90 in paediatric HIV: What is needed?HCV-HIV coinfected pregnant women: data from a multicentre study in Italy.Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and IrAntiretroviral therapy during pregnancy and premature birth: analysis of Swiss data.Risk factors of HIV-1 vertical transmission (VT) and the influence of antiretroviral therapy (ART) in pregnancy outcome.Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenBirth outcome in HIV vertically-exposed children in two Romanian centers.Combination antiretroviral use and preterm birth.Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.Laboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025Antiretroviral use during pregnancy for treatment or prophylaxis.Antiretroviral therapy and preterm birth in HIV-infected women.Adverse drug reactions associated with antiretroviral therapy during pregnancy.Tolerance of the newborn to antiretroviral drug exposure in utero.Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.Antiretroviral Therapy in Relation to Birth Outcomes among HIV-infected Women: A Cohort Study.Inflammatory Markers Related to Microbial Translocation Among HIV-Infected Pregnant Women: A Risk Factor of Preterm Delivery.Rate, predictors, and consequences of late antenatal booking in a national cohort study of pregnant women with HIV in Italy.Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission.Pregnancy outcomes in HIV-infected women of advanced maternal age.Antiretrovirals in pregnancy: a note of caution.Protective effect of indoor residual spraying of insecticide on preterm birth among pregnant women with HIV in Uganda: A secondary data analysis.Glucose plasma levels and pregnancy outcomes in women with HIV.Impact of Timing of Antiretroviral Treatment and Birth Weight on Mother-to-Child Human Immunodeficiency Virus Transmission: Findings From an 18-Month Prospective Cohort of a Nationally Representative Sample of Mother-Infant Pairs During the TransitiFactors Influencing Gestational Age-Adjusted Birthweight in a National Series of 600 Newborns from Mothers with HIV
P2860
Q28066290-1376381F-0FC1-4C14-B6F8-F0E356B532E7Q30385352-691546D6-CABF-48A8-B49B-E0ED409D190EQ31011972-642E22CE-6468-4B68-BF72-E6CFE175940DQ31043161-5906B4A2-2246-40E2-8E12-3CDF6EA7E77DQ33667399-D82BD496-DB2C-4201-8AA2-E891577813CCQ33859660-4776233B-1508-42F5-97DD-CA84E092AEDDQ34158407-F007AF76-E001-4A40-BFE1-90AC1C0F5ABEQ35551457-A3116925-C12C-4DE8-A561-98AF5371E31BQ35691443-A5228599-89BD-49F0-B6A4-2C3609E5B405Q35921113-279EA4C1-F778-431C-B4EC-88F9BAE783D4Q36349683-7828B942-4112-4340-BC31-8708574A8709Q36404388-52078DDF-C195-4753-AB39-0147140305A1Q36547343-B4AAC12A-2872-44A4-93D9-59115001FC91Q36816616-6E5989A3-D366-42ED-9FBA-3B946A57004EQ36851168-4DB62E5C-39B9-4C01-A53E-868EB504C416Q37870932-2593019C-DA01-4558-893E-49F91DC7F63BQ38185748-1079DE86-4432-426D-A560-8AEDDE20FF12Q38267557-42095871-6C6C-427D-AFAF-0A3DC2E5A613Q38366365-65A0536C-D59B-43C8-BA5D-5CBEB8BF4D8BQ38636802-AE3918AE-F656-410A-9F58-53CCFEED03B2Q41057198-36E8AA28-068B-4439-9F64-EA1984135F12Q41057213-36EA99E7-FD63-45B9-ADB7-AE09008F407BQ42209715-494C2874-C0A3-470F-909A-CD6C0C801156Q42248173-6B128EC8-A20E-4AF4-BBC9-EFA393F04290Q42255965-D4912A6D-3C90-41CF-9662-504486A0DFABQ42333841-B2309F46-5D42-49BF-9635-00217A98F8F5Q46129994-549186C8-77D0-45C0-BF50-13242F7C67B9Q51363612-A5171E04-6A42-4105-A11C-1393FFBDF69EQ52699623-0781286E-6954-48BF-90F0-96612F7E5056Q56880897-63EDC305-E1B7-4019-87BB-E750A6310E68
P2860
Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Treatment with protease inhibi ...... n HIV-infected pregnant women.
@en
Treatment with protease inhibi ...... n HIV-infected pregnant women.
@nl
type
label
Treatment with protease inhibi ...... n HIV-infected pregnant women.
@en
Treatment with protease inhibi ...... n HIV-infected pregnant women.
@nl
prefLabel
Treatment with protease inhibi ...... n HIV-infected pregnant women.
@en
Treatment with protease inhibi ...... n HIV-infected pregnant women.
@nl
P2093
P50
P356
P1476
Treatment with protease inhibi ...... in HIV-infected pregnant women
@en
P2093
A Maccabruni
Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy
M P Crisalli
P Martinelli
S Alberico
P304
913-4; author reply 916-7
P356
10.1086/507045
P407
P577
2007-03-01T00:00:00Z